ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.91) by 19.78 percent. This is a 4.29 percent decrease over losses of $(0.70) per share from the same period last year.
Semiconductor Shortages – See How ResMed Is Tackling
ResMed Inc (NYSE: RMD) has redesigned the AirSense 10 to eliminate a short-supply semiconductor chipset used for cellular communications chips.